Examorelin

Examorelin

SCHEMBL19816240

CC[N+](CC)(CC)CC.Cc1[nH]c2ccccc2c1C[C@@H](NC(=O)[C@@H](N)Cc1c[nH]cn1)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(N)=O

nearest known ligand 0.57

Full drug profile on Sugi Atlas →

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
▸ GHSR Q92847 13/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Examorelin SCHEMBL29403103 0.97 GHSR (0.60) GHSR
Examorelin SCHEMBL26959 0.97 GHSR (0.60) GHSR
Examorelin SCHEMBL28022186 0.97 GHSR (0.60) GHSR
Examorelin SCHEMBL29805730 0.97 GHSR (0.60) GHSR
Examorelin SCHEMBL6219689 0.96 GHSR (0.59) GHSR
Examorelin SCHEMBL8580589 0.96 GHSR (0.59) GHSR
SCHEMBL21118232 0.92 GHSR (0.64) GHSR
SCHEMBL30675098 0.91 GHSR (0.66) GHSR
SCHEMBL9726175 0.91 GHSR (0.66) GHSR
SCHEMBL9726172 0.91 GHSR (0.66) GHSR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3506926-A1 NEUROMODULATING COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES Flagship Pioneering Innovations V, Inc. (US) 2019-07-10 — — EP disclosed
EP-3490542-A1 NEUROMODULATING COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF CANCER BY MODULATING AN ANTI-CANCER IMMUNE RESPONSE Flagship Pioneering Innovations V, Inc. (US) 2019-06-05 — — EP disclosed
EP-3490581-A2 NEUROMODULATING COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF CANCER Flagship Pioneering Innovations V, Inc. (US) 2019-06-05 — — EP disclosed
WO-2018022666-A1 NEUROMODULATING COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF CANCER BY MODULATING AN ANTI-CANCER IMMUNE RESPONSE FLAGSHIP PIONEERING, INC. (US) 2018-02-01 — — WO disclosed
WO-2018022668-A2 NEUROMODULATING COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF CANCER FLAGSHIP PIONEERING, INC. (US) 2018-02-01 — — WO disclosed
WO-2018022664-A1 NEUROMODULATING COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES FLAGSHIP PIONEERING, INC. (US) 2018-02-01 — — WO disclosed
Send feedback